Multistage Malaria Vaccine Achieves 54% Efficacy in Phase 2 Trial Among Malian Adults
核心洞察
A phase 2 randomized controlled trial of the investigational multistage malaria (搜索) vaccine ProC6C-AlOH/Matrix-M (搜索) demonstrated 54% efficacy against controlled human malaria infection in Malian adults with lifelong parasite exposure.
The vaccine targets multiple stages of the Plasmodium falciparum (搜索) life cycle and represents the first anti-P. falciparum subunit vaccine to surpass 50% efficacy against controlled human malaria (搜索) infection at 12 weeks post-vaccination.
Researchers noted this achievement as significant for the malaria (搜索) community, which has reached consensus on the need to target as many parasite stages as possible in vaccine development.
A novel multistage malaria (搜索) vaccine candidate has demonstrated promising efficacy in a phase 2 randomized controlled trial, achieving 54% protection against controlled human malaria infection in adults with lifelong exposure to the parasite. The results, published in The Lancet Infectious Diseases, represent a significant milestone in malaria vaccine development as the first anti-Plasmodium falciparum (搜索) subunit vaccine to exceed 50% efficacy at 12 weeks post-vaccination.
Trial Design and Participants
Researchers from the Malaria Research and Training Center (搜索) at the University of Sciences, Techniques, and Technologies of Bamako (搜索), along with collaborators from Europe and US-based Sanaria (搜索), conducted the study among 34 healthy adults aged 18 to 50 years in Mali, a malaria (搜索)-endemic region. The participants were randomly assigned to receive either three doses of the investigational vaccine ProC6C-AlOH/Matrix-M (搜索) (17 volunteers) or three doses of rabies vaccine as controls (17 volunteers), administered four weeks apart.
Ninety-four days after the final dose, participants underwent controlled human malaria (搜索) infection through injection of a small amount of the malaria parasite under the skin. Of the 32 participants who completed the challenge, researchers monitored for the development of parasites in the bloodstream over 28 days.
Efficacy Results
The vaccine demonstrated notable protective effects against malaria (搜索) infection. Among participants who completed the challenge, 59% developed parasitemia within 28 days. Infection occurred in 13 of 16 control recipients compared with six of 16 vaccine recipients, yielding a vaccine efficacy of 54% (95% CI 9–77, p=0.029).
In a time-to-event analysis, the vaccine showed even stronger performance with 76% efficacy (95% CI 36–91, p=0.0022). Among those who became infected, vaccination delayed the median time to detectable parasitemia by 2 days compared to controls.
Safety Profile
Adverse events were more common in the vaccine group compared to controls, but researchers noted that almost all events were mild in severity. The safety profile supports continued development of the vaccine candidate.
Targeting Multiple Parasite Stages
ProC6C-AlOH/Matrix-M (搜索) represents an innovative approach to malaria (搜索) prevention by targeting multiple stages of the Plasmodium falciparum (搜索) life cycle. This multistage strategy addresses both infection and transmission, offering a comprehensive approach to malaria control.
In a related commentary published in The Lancet, researchers emphasized the significance of this achievement: "Having a first multistage malaria (搜索) vaccine with proven efficacy is a key achievement, as there is consensus in the malaria community on the need to cover as many parasite stages as possible."
Global Malaria Burden
The study results come at a critical time in the fight against malaria (搜索), which remains a significant global health challenge. Malaria transmission occurs in 80 countries across five WHO regions, with the World Health Organization reporting an estimated 282 million cases globally last year.
Future Research Directions
The study authors acknowledge that further research is needed to evaluate the vaccine's performance against naturally acquired malaria (搜索) and in younger age groups, including children. These next steps will be crucial for determining the vaccine's potential real-world impact in malaria-endemic populations.
The researchers noted that this represents the first anti-P. falciparum subunit vaccine to surpass 50% efficacy against controlled human malaria (搜索) infection at 12 weeks after vaccination, suggesting "a novel, strong, and mechanistically plausible correlate of protection."